Aprogen Medicines Inc. (KRX:007460)

Aprogen Medicines Revenue

Aprogen Medicines had revenue of 35.53B KRW in the quarter ending June 30, 2026, with 52.90% growth. This brings the company's total for the last twelve months to 138.90B, up 9.08% year-over-year. In the year 2025, Aprogen Medicines had annual revenue of 117.97B, down -21.41%. That makes Aprogen Medicines the 22,297th largest company in the world by revenue and 1,250th in South Korea.

• Revenue (ttm): 138.90B
• Revenue Growth: +9.08%
• P/S Ratio: 0.31
• Revenue / Employee: 868.13M
• Employees: 160
• Market Cap: 42.20B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medicines 59.41B 50.4%
• Metal Sector 35.58B 30.2%
• Semiconductor 9.64B 8.2%
• Geothermal Construction 7.49B 6.4%
• Bio Sector 2.94B 2.5%
• Insulation Business Division 2.42B 2.1%
• Other 496.95M 0.4%

By Geography

Chart

• South Korea 111.80B 94.8%
• Overseas 6.18B 5.2%

Fiscal year ended Dec 31, 2025 See the full Aprogen Medicines breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	117.97B	-32.14B	-21.41%
Dec 31, 2024	150.11B	-464.40M	-0.31%
Dec 31, 2023	150.58B	72.23B	92.19%
Dec 31, 2022	78.35B	52.05B	197.95%
Dec 31, 2021	26.30B	-100.85B	-79.32%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error